These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Status of Immune Oncology: Challenges and Opportunities. Cesano A; Marincola FM; Thurin M Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145 [TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034 [TBL] [Abstract][Full Text] [Related]
12. Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. Parra ER; Ferrufino-Schmidt MC; Tamegnon A; Zhang J; Solis L; Jiang M; Ibarguen H; Haymaker C; Lee JJ; Bernatchez C; Wistuba II Sci Rep; 2021 Apr; 11(1):8511. PubMed ID: 33875760 [TBL] [Abstract][Full Text] [Related]
13. Microenvironmental regulation of tumour immunity and response to immunotherapy. Kockx MM; McCleland M; Koeppen H J Pathol; 2021 Jul; 254(4):374-383. PubMed ID: 33846997 [TBL] [Abstract][Full Text] [Related]
14. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Duan J; Wang Y; Jiao S Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347 [TBL] [Abstract][Full Text] [Related]
15. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
16. Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures. Wang T; Li T; Li B; Zhao J; Li Z; Sun M; Li Y; Zhao Y; Zhao S; He W; Guo X; Ge R; Wang L; Ding D; Liu S; Min S; Zhang X Front Immunol; 2022; 13():805184. PubMed ID: 35154121 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382 [TBL] [Abstract][Full Text] [Related]
20. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]